Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Pharmaceuticals released long-term data from its Phase 2 BESTOW clinical trial demonstrating that tegoprubart, an investigational anti-CD40L antibody, maintained superior kidney function compared to tacrolimus in kidney transplant recipients, with significantly higher eGFR at 18 months and no biopsy-proven acute rejection events after six mo…